Brief: Lyra Therapeutics Inc Wins Award At The 67Th Annual Meeting Of The American Rhinologic Society
04/10/2021 12:19
Oct 4 (Reuters) - Lyra Therapeutics Inc LYRA.O :
* LYRA THERAPEUTICS PRESENTS NEW POSITIVE PHASE 2 LANTERN
6-MONTH
FOLLOW-UP AND LYR-210 PHARMACOKINETIC DATA, AND LANTERN
MANUSCRIPT WINS AWARD AT THE 67TH ANNUAL MEETING OF THE AMERICAN
RHINOLOGIC SOCIETY
* LYRA THERAPEUTICS INC - APPROXIMATELY 50% OF TREATED CRS
PATIENTS EXPERIENCED DURABLE SYMPTOM IMPROVEMENT SIX MONTHS
AFTER TREATMENT WITH LYR-210
* LYRA THERAPEUTICS INC - LYR-210 PHARMACOKINETICS INDICATE
A
CONSTANT AND STEADY DAILY DOSE OF MOMETASONE FUROATE IS
DELIVERED TO PATIENTS
* LYRA THERAPEUTICS INC - LYR-210 WAS SAFE AND
WELL-TOLERATED WITH
ZERO SERIOUS ADVERSE EVENTS, AND ACHIEVED 100% PLACEMENT SUCCESS
Source text for Eikon: ID:nPn3wng66a
Further company coverage: LYRA.O